产品名称

英文名称：Empagliflozin (BI 10773)

同义词

Empagliflozin、864070-44-0、JARDIANCE、BI 10773、BI10773、BI-10773、Empagliflozin (BI 10773)、UNII-HDC1R2M35U、HDC1R2M35U、(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol、CHEBI82720、依帕列净、恩格列净

产品性质

CAS编号：864070-44-0

分子式：C23H27ClO7

分子量：450.91

PubChem编号：11949646

别名：依帕列净|恩格列净

英文别名：Empagliflozin|864070-44-0|JARDIANCE|BI 10773|BI10773|BI-10773|Empagliflozin (BI 10773)|UNII-HDC1R2M35U|HDC1R2M35U|(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol|CHEBI82720|

规格或纯度：≥99%

英文名称：Empagliflozin (BI 10773)

生化机理：Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. Blocking SGLT-2 causes blood glucose to be eliminated throμgh the urine via the urethra. The Empagliflozin phase III clinical trial program will include about 14,500 patients. The program consists of twelve ongoing international phase III clinical trials, including a large cardiovascular outcomes trial.

储存温度：-20°C储存

运输条件：超低温冰袋运输

备注：5mg,25mg,100mg卖完停产，不再备货

产品介绍：Empagliflozin (BI 10773)是一种有效的，选择性SGLT-2抑制剂，IC50为3.1 nM，比作用于SGLT-1， 4， 5和6选择性高300倍以上。Phase 3。Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.

ALogP：2

PubChem SID：488197794

PubChem SID url：https//pubchem.ncbi.nlm.nih.gov/substance/488197794

IUPAC Name：(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

INCHI：InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1

InChi Key：OBWASQILIWPZMG-QZMOQZSNSA-N

Canonical SMILES：C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl

Isomeric SMILES：C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl

关联CAS：864070-44-0

PubChem CID：11949646

MeSH Entry Terms：1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene;BI 10773;BI-10773;BI10773;empagliflozin;Jardiance

Wikipedia：Empagliflozin

CAS Registry No.：864070-44-0

ChEMBL Ligand：CHEMBL2107830

ChEBI：CHEBI82720

PEP：empagliflozin

DrugCentral Ligand：4830

RCSB PDB Ligand：7R3

溶解性：DMSO 90 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

象形图：

信号词：Warning

危险声明：H302 Harmful if swallowedH361 Suspected of damaging fertility or the unborn childH362 May cause harm to breast-fed children

预防措施声明：P280,P405,P501,P264,P260,P270,P330,P263,P203,P301+P317,P318

产品包装